Shorla Oncology

Shorla Oncology is a pioneering pharmaceutical startup dedicated to the development and commercialization of innovative oncology medicines, with a particular focus on women's and pediatric cancers. The company's mission is to address the unmet needs in cancer treatment by targeting indications where existing therapies are limited, in shortage, or inadequate for the target population. Shorla Oncology’s impressive product portfolio is the result of a world-class team of thought leaders, clinicians, scientists, and commercial strategists, all of whom have extensive experience in drug development and the commercialization of niche cancer treatments. Founded in 2018, Shorla Oncology is poised to make a significant impact on patient care by bringing accessible, affordable, and life-saving treatments to those in need. With a strong emphasis on delivering clinical impact, the company is committed to providing a major contribution to the field of oncology. Although specific investment and headquarters details are not available at this time, Shorla Oncology's forward-thinking approach and commitment to addressing critical gaps in cancer treatment make it a compelling prospect for venture capital investment.